Metabolic reprogramming characterized by mitochondrial dysfunction and increased glycolysis is associated with aggressive tumor biology and poor therapeutic response. The interplays among NADPH oxidase (NOX)-mediated reactive oxygen species, regulation of glycolysis and oxidative phosphorylation (OXPHOS) in cancer cells suggest an opportunity to develop a new cancer therapy. We found that treatment with a hyaluronic acid nanoparticle encapsulated with GKT831 (HANP/GKT831), a NOX1/4 inhibitor, markedly inhibited the proliferation and invasion of cancer cells. Treated tumor cells had reduced levels of mitochondrial ROS, glycolysis, and OXPHOS. The combination of HANP/GKT831 with radiation reduced colony formation and invasion of tumor cells. The combination therapy markedly inhibited the levels of molecules in glycolysis, OXPHOS, and DNA repairing pathways in tumor cells. Systemic administrations of HANP/GKT831 combined with radiotherapy significantly inhibited tumor growth by 84.7 % in a mouse colorectal tumor model. Tumors treated with HANP/GKT831 and radiation had increased DNA damage and apoptotic cell death. Furthermore, the combined therapy increased intratumoral infiltration of activated cytotoxic T cells and M1 macrophages but reduced the levels of immunosuppressive fibroblasts and M2 macrophages. Our results support HANP/GKT831 as a cancer nanotherapeutic agent that induces redox and bioenergy stresses in cancer cells for enhanced therapeutic response to radiotherapy.

Introduction:Combination therapy is a promising approach to promote the efficacy and reduce the systemic toxicity of cancer therapy. Herein, we examined the potency of a combined chemo-phototherapy approach by constructing a hyaluronidase- and reactive oxygen species-responsive hyaluronic acid nanoparticle carrying a chemotherapy drug and a photosensitizer in a tumor-bearing mouse model. We hypothesized that following decomposition, the drugs inside the nanocomplex will be released in the tumors to provide effective tumor treatment. We aimed to design a smart drug delivery system that can improve traditional chemotherapy drug delivery and enhance the therapeutic efficacy in combination with photodynamic therapy.Methods:Hydrophilic hyaluronic acid (HA) was covalently modified with a hydrophobic 5β-cholanic acid (CA) via an ROS-cleavable thioketal (tk) linker for a targeted co-deliver of 10-Hydroxy camptothecin (HCPT) and Chlorin e6 (Ce6) into tumors to improve the efficiency of combined chemo-photodynamic therapy.Results:The obtained HA-tk-CA nanoparticle carrying HCPT and Ce6, named HTCC, accumulated in the tumor through the enhanced permeable response (EPR) effect and HA-mediated CD44 targeting after intravenous administration. Upon laser irradiation and hyaluronidase degradation, HTCC was disrupted to release HCPT and Ce6 into the tumors. Compared to the monotherapy approach, HTCC demonstrated enhanced tumor growth inhibition and minimized systemic toxicity in a tumor-bearing mouse model.Conclusion:Our results suggested that controlled dual-drug release not only improved tumor drug delivery efficacy, but also reduced systemic side effects. In addition to HCPT and Ce6 delivery, the HA-tk-CA nanocomplex can be used to deliver other drugs in synergistic cancer therapy. Since most current combined therapy uses free drugs with distinct spatiotemporal distributions, the simultaneous co-delivery of dual drugs with a remote on-demand drug delivery nanosystem provides an alternative strategy for drug delivery design.

One of the main reasons why most cancer patients do not respond well to chemotherapy is that drugs cannot accumulate in tumors at an optimal dose, eventually resulting in failure to prevent cancer cell growth. To improve drug delivery efficiency, we engineered a highly efficient tumor-targeted and stroma-breaking nanocarrier by the modification of iron oxide nanoparticles (IONPs) with a tumor-targeting peptide c(RGDyK) and a hyaluronidase (HAase) on the surface. The yielding nanocomplex, c(RGDyK)-HAase-IONP, targeted the tumor by binding integrin αvβ3 and went deeply into the tumors by the degradation of hyaluronic acid (HA), which was highly expressed in the tumor extracellular matrix (ECM). Good biostability and a low pH preferred drug release profile were characterized for c(RGDyK)-HAase-IONP carrying DOX in vitro. c(RGDyK)-HAase-IONP showed an improved tumor-targeting (2.5 times higher) effect after intravenous injection in the MC38 tumor-bearing mice model, as determined by whole-body fluorescence imaging compared to the non-targeted IONPs without HAase. After 5 systemic treatments, c(RGDyK)-HAase-IONP/DOX (5 mg/kg of equivalent dose of DOX) significantly inhibited MC38 tumor growth (22.1 ± 7.4 times relative to the non-treated group). Elevated apoptosis and reduced proliferation in the tumor cell were detected in the c(RGDyK)-HAase-IONP/DOX treated tumors compared to the control groups. Overall, the highly efficient targeted nanocarrier c(RGDyK)-HAase-IONP demonstrated tremendous potency for improving drug delivery and tumor therapy efficacy by targeted degradation of the dense HA barrier in the tumor ECM. We determined that such a tumor stroma-degrading nanosystem was capable of reducing tumor recurrence and drug resistance and could ultimately improve clinical tumor treatment responses.

Large quantities of microplastics are found in the East China Sea (ECS), however, the impacts of complicated terrestrial input on the distribution characteristics of microplastics have not been studied. Hence, we aimed to characterize the microplastic distribution in the ECS combined with the fluorescence characteristics of chromophoric dissolved organic matter (CDOM), a sensitive technique to trace terrestrial substances in seawater. The average microplastic abundance in the surface seawater of ECS was 34.73 ± 4.05 items/m3 and sites in the north ECS had a higher microplastic abundance (55.90 ± 2.47 items/m3) than those in the southern region (11.22 ± 4.01 items/m3), due to its proximity to the Yangtze River estuary and Hangzhou Bay. Polyethylene (PE, 44.2 %) was the most abundant microplastic type in the northern region, whereas polyethylene terephthalate (PET, 28.4 %) had a higher proportion in the south ECS. Besides, sites in the north ECS had a higher diversity index of microplastics, suggesting various sources of microplastic pollution. Interestingly, a stronger correlation with the diversity index was found for protein-like component C3 (R2 = 0.56) in northern regions compared to fulvic-like component C1 (R2 = 0.32) and humic-like component C2 (R2 = 0.28), suggesting the significant impact of anthropogenic discharge. Moreover, no correlation between fluorescence components and microplastic diversity index was found in the south ECS, indicating that CDOM can reflect the impact range of terrestrial input on the distribution characteristics of microplastics. This research might be useful in assessing and reducing the impact of terrestrial input on the distribution characteristics of microplastics in the ECS.

Cancer and cardiovascular diseases are the leading causes of death globally. Given the high percentage of cancer patients with co-existing atherosclerosis due to many shared risk factors, the development of novel cancer therapeutic agents with strong anti-tumor efficacy and therapeutic benefit on atherosclerosis can significantly improve the outcome of cancer therapy. Immune checkpoint inhibition (ICI) therapy using therapeutic antibodies has shown promises in the treatment of several types of human cancers. However, many cancer patients showed a poor response due to low delivery efficiency, lack of effector T cells, an immunosuppressive tumor microenvironment, and intrinsic resistance in solid tumors. Increasing numbers of patients developed immunotherapy related adverse effects (irAEs). It is well known that macrophages and effector T cells drive the progression of atherosclerosis. Recent clinical studies revealed that cancer patients received ICI therapy have 3-fold higher risk of atherosclerosis and 3-fold increases in plaque progression detected by PET imaging. To enhance therapeutic efficacy of tumor immunotherapy and decrease irAEs, we have developed a hyaluronic acid nanoparticle (HANP) conjugated with PD1 mimetic peptides that target and block PD-L1 function, and encapsulated with Avasimibe (PD1Y-HANP/Ava). Avasimibe is a multifunctional agent that decreases cholesterol accumulation, inhibits tumor growth, and enhances immune response by activating cytotoxic T cells. We found that systemic administrations of PD1Y-HANP/Ava led to targeted delivery into tumors and atherosclerotic plaques in a dual colon cancer and atherosclerosis mouse model, established by injecting mouse colon tumor cells into Apoe knockout mice on a high fat diet. PD1Y-HANP/Ava treatments resulted in 78% of tumor growth inhibition. Following surgical resection of residual tumors, 80% of PD1Y-HANP/Ava treated mice had disease-free survival of >120 days and were protected from tumor growth after tumor cell re-challenging. Histological analysis of the major arteries revealed that the volume of atherosclerotic plaques decreased 70% in the mice treated with PD1Y-HANP/Ava compared the no-treated mice. Our results showed that PD1Y-HANP/Ava treatment increased infiltration of CD8+ T effector and dendritic cells, and activated cytotoxic T cells in mouse colon tumors. Colon tumor specific antibodies were detected in the mouse serum following PD1Y-HANP/Ava treatment. However, the levels of CD8+ T cells, dendritic cells, and macrophages were decreased in the atherosclerotic plaques, which could prevent ICI-induced cardiovascular irAEs. Results of this study should provide us with preclinical evidence for translational development of targeted immunotherapy for colon cancer patients with comorbid atherosclerosis. Citation Format: Lei Zhu, Weiping Qian, Minglong Chen, Tongrui Liu, Charles A. Staley, Bassel El-Rayes, Hanjoong Jo, Lily Yang. Development of an immune modulating and tumor inhibiting hyaluronic acid nanoparticle encapsulated with Avasimibe for the treatment of cancer patients with comorbid atherosclerosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 4152.

The behavior of microplastics in wastewater treatment plants has been investigated, but specific effects of treatment process on microplastics' fate are still unclear due to varied analysis methods and regional differences. In this study, four wastewater treatment plants in Ningbo of southeastern China with different treatment processes were selected to investigate transport and fate of microplastics. Based on number of microplastic particles, fibers and fragments were the main microplastics types in wastewater, while synthetic cellulose represented the largest fraction. The dominance of fibers (76.7%-90.0%) and small particle sizes (<2.0 mm, 62.5%-81.5%) in effluents suggested that they escaped easily from the wastewater treatment plants. The abundance of microplastics particles decreased from 78.0 ± 2.9 items/L in influent to 6.0 ± 2.8 items/L in effluent for anaerobic-anoxic-oxic process, 100.0 ± 3.1 items/L to 4.3 ± 3.4 items/L for sequencing batch reactor activated sludge process, 105.0 ± 5.3 items/L to 3.5 ± 2.6 items/L for cyclic activated sludge technology, 65.0 ± 4.3 items/L to 3.0 ± 1.6 items/L for oxidation ditch process. The microplastics removal capacity of primary and secondary treatment processes for four wastewater treatment plants ranged from 83.7% to 96.3%. Application of different tertiary treatment processes (coagulation/flocculation, membrane related technology and disinfection) enhanced microplastics removal to achieve overall removal rate of 92.3%-96.7%. The removed microplastics from the wastewater treatment plants were mainly transferred to sludge (226.1 ± 95.7-896.0 ± 144.0 items/g dry weight). The biological treatment unit played an important role in microplastics removal with rates varying between 86.9%-95.2%, while tertiary treatment reduced daily microplastics emission 1.4 × 108-2.3 × 108 items/day. This study suggests that proper selection of wastewater treatment unit could significantly reduce the emission number of microplastics, which supports an efficient control strategy of microplastics in wastewater treatment plants.

Upregulation of NADPH oxidases (NOXs) in cancer cells leads to chronic increase in intracellular reactive oxygen species (ROS) and adaptation to a high ROS level for cell survival and, thereby, low sensitivity to radiotherapy. To overcome resistance to radiotherapy, we have developed a bioactive and CD44 targeted hyaluronic acid nanoparticle encapsulated with an NOX inhibitor, GKT831 (HANP/GKT831). We found that HANP/GKT831 had stronger inhibitory effects on ROS generation and cell proliferation than that of GKT831 alone in cancer cells. Systemic delivery of HANP/GKT831 led to the targeted accumulation in breast cancer patient derived xenograft (PDX) tumors in nude mice. Importantly, the combination of systemic delivery of HANP/GKT831 with a low dose of local radiotherapy significantly enhanced tumor growth inhibition in breast cancer PDX models. Our results showed that HANP/GKT831 primed tumor cells to radiation-induced DNA damage and cell death by downregulation of DNA repair function and oncogenic signal pathways.

The human epidermal growth factor receptor-2-positive (HER2+) type is aggressive and has poor prognosis. Although anti-HER2 therapy alone or in combination with other treatment regimens showed significant improvement in survival outcomes, breast cancer patients are still suffering from tumor relapse and severe dose -limiting side effects. Thus, there is still an unmet challenge to develop effective therapeutic agents for HER2+ breast cancer treatment with minimized side effects. Herein, we produced a stimuli-responsive and tumor -targeted hyaluronic acid (HA) nanocomplex that combined HER2 blockade and chemotherapy for effective HER2+ breast cancer therapy. A hydrophobic NIR-II dye, IR1048, was covalently linked with HA to form a spherical HA-IR1048 nanoparticle (HINP), with Herceptin conjugated on the surface and paclitaxel (PTX) encapsulated inside. The fluorescent signals from the yielding Her-HINP/PTX are quenched originally, but a strong NIR-II signal is generated when HINP is degraded by the hyaluronidase that is overexpressed in breast tumors, thus allowing the tracking and visualization of Herceptin and PTX accumulation. Her-HINP/PTX peaked in HER2+ tumors at 24 h post injection as imaged by NIR-II fluorescent imaging. A significantly improved tumor growth inhibition effect was observed after five systemic treatments compared to single PTX (3.71 +/- 0.41 times) or Herceptin (5.98 +/- 0.51 times) treatment in a HER2-overexpressed breast cancer mouse model with prolonged survival. Collectively, the designed Her-HINP/PTX presents a new hyaluronidase-responsive and HER2 blockade nanoformulation that can visualize the accumulation of nanocomplexes and release drugs inside tumors for combined HER2+ breast cancer therapy with a great promise for translational study.Statement of significance: The high expressions of a protein called human epidermal growth factor receptor 2 (HER2) in breast tumors make this subtype of cancer aggressive. Currently, chemotherapy combined with a HER2 antibody, Herceptin, is a preferred approach for HER2-positive breast cancer therapy. However, these breast cancer patients still suffer from tumor relapse and severe side effects because various therapeutic agents have inherent different biodistributions, resulting in insufficient treatment effects and unfavorable normal organ uptake of these therapeutic agents. Herein, we produced a nanocomplex carrying both Herceptin and chemo-therapy drug to simultaneously deliver two drugs into tumors for efficient HER2+ tumor treatment with mini-mized side effects, providing new insights for designing a combined therapy strategy.

Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that the tumor images shown in Fig. 6B bore unexpected similarities to data appearing in different form in other articles by different authors. In addition, there were potential anomalies associated with the cell migration assay data shown in Fig. 2E. Owing to the fact that some of the contentious data in the above article had already been published elsewhere, or were already under consideration for publication, prior to its submission to Oncology Reports, the Editor has decided that this paper should be retracted from the Journal. The authors agree with the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in Oncology Reports 39: 695-702, 2018; DOI: 10.3892/or.2017.6119].

随着"陆海统筹"海洋保护战略的提出,近海水质修复越来越依靠对污染源数据的准确掌握,而活性磷酸盐和总无机氮等常规水质指标不能对海洋中陆源污染物进行有效指示.因此,本研究利用三维荧光光谱结合平行因子分析（EEM-PARAFAC）等技术分析了象山港和东海不同深度有色溶解性有机质（CDOM）的组成和分布特征,探讨基于CDOM快速分析技术的近海水质评价方法.结果表明,象山港水质受沿岸排放影响显著,其氮磷营养盐、陆源腐殖质（EEM-PARAFAC组分C1和C4）和生活源类蛋白质（C3和C5）物质显著高于东海表层水体.在东海水体中,5个荧光组分的高值区主要分布在北部近岸表层海域,与盐度分布相反,清晰表明长江冲淡水等陆源输入对CDOM的显著影响.相关性分析表明,陆源物质输入是东海表层水体中污染物的重要来源,而底层污染物的来源则更为复杂.总体上,污水类物质较大程度地改变了东海北部表层CDOM的组成.本研究表明,利用EEM-PARAFAC等技术可快速有效地识别海洋中CDOM的来源,深刻揭示了陆源排放对海洋水质的影响程度,可为"陆海统筹"海洋保护策略提供技术支撑.

Anin vivoandin vitrotwo-step phage display screening approach to identify Glypican-3 targeting peptides for the detection of hepatocellular carcinoma with low normal liver uptake.

Melanoma (MM) is a highly aggressive skin cancer with limited treatment options. Although chemotherapy has been using for advanced melanoma treatment, the lack of targetability, the poor biocompatibility and the severe side effects still hamper the wide applications of chemotherapy agents in MM management. Herein, a biocompatible and biodegradable polymeric hyaluronic acid nanoparticle (HANP) encapsulated with Paclitaxel (PTX) was developed for MM targeted therapy. Our results showed that PTX at 37 ± 2.1% (w/w) was able to be loaded into HANP with over 5 d of stability under physiological conditions. In vitro, HANP/PTX presented hyaluronidase-dependent drug release. Compared to free PTX, HANP/PTX demonstrated a 6–75 times higher growth inhibition in five different cancer cells, while only presenting minimum toxicity to normal cells. After intravenous administration at a 10 mg kg−1 equivalent dose of PTX, HANP/PTX significantly ablated MM tumor growth in a mouse model. As confirmed by 18F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) imaging, the tumors started to respond to the HANP/PTX as early as 7 d after the initial treatment, which will significantly benefit for personalized treatment. In conclusion, the HANP/PTX nanocomplex demonstrated great promise as a translational nanomedicine for cancer chemotherapy.

Introduction : Pulmonary vein isolation (PVI) has become a favor strategy during atrial fibrillation ablation, but occasionally additional linear ablation would be performed to achieve a better outcomes. When left anterior wall linear ablation (LAWA) was taken, it might impair the Backmann Bundle (BB) eventually. This study aims to investigate those features of surface electrocardiogram (EKG) and clues to indicate the impairment of BB after LAWA.

3026 Objectives: Early monitoring the treatment effect is very helpful for in vivo evaluation of the drug potential and clinical doctors to adjust the therapeutic regimen. Methods: In this study, a dual targeted nanodrug, hyaluronic acid nanoparticles (HANPs) encapsulated with paclitaxel (PTX), was investigated. Preclinically, PTX-loaded HANPs (HANPs/PTX) showed dose-dependent cytotoxicity to cancer cells (HT29, A549, MDA-MB-231, HepG2 and MDA-MB-435s) and significantly lower cytotoxicity against normal fibroblasts (NIH-3T3) than free PTX. In vivo, we intravenously administered PBS, free paclitaxel, paclitaxel protein-bound particles (Abraxane) and HANPs/PTX to each group of athymic nude mice with MDA-MB-435s breast tumors. To monitor therapeutic responses, PET scans were obtained before and at different times after the start of treatment (days 0, 3, 7 and 14) using 18F-FDG. Results: As expected, the control group, treated with saline and free PTX, exhibited a rapid increase in tumor size as a function of time. Significant slower increase in tumor size was found for the group treated with HANPs/PTX or Abraxane. On HANPs/PTX treatment, the tumor uptake of 18F-FDG is less than the untreated tumors’ in a day-7 to day-0 ratio (0.51:1.30). Conclusions: Overall, HANPs showed the promising potential as a dual targeted drug carrier for cancer therapy and the early detection treatment effect was optimal with PET monitoring of therapeutic responses.

Mariculture activities including enclosure, raft and cage cultures employ a variety of plastic gear such as fishing nets, buoyant material and net cages. The plastic gear poses a potential source of microplastics to the coastal environment, but relevant data on the impacts of mariculture are still limited. To this end, a semi-enclosed narrow bay (i.e., Xiangshan Bay, China) with a long-term mariculture history was investigated to assess how mariculture activities affect microplastics in seawater and sediment. The results indicated that mariculture-derived microplastics accounted for approximately 55.7% and 36.8% of the microplastics in seawater and sediment, respectively. The average microplastic abundances of seawater and sediment were 8.9 ± 4.7 (mean ± SD, n = 18) items/m3 seawater and 1739 ± 2153 (n = 18) items/kg sediment, respectively. The types of mariculture-derived microplastics included polyethylene (PE) foam, PE nets, PE film, polypropylene (PP) rope, polystyrene (PS) foam and rubber. PE foam had the highest proportion (38.6%) in the seawater samples. High usage rates and the porous structure of PE foam led to the high abundance. The average microplastic sizes of seawater and sediment are 1.54 ± 1.53 mm and 1.33 ± 1.69 mm, respectively. The spatial variations in the abundance and size of microplastics implied that the mariculture-derived microplastics in Xiangshan Bay were transported along the Bay to the open sea. The results of this study indicate that mariculture activity can be a significant source of microplastics. Further research is required to investigate how the high microplastic abundance in mariculture zone affects marine organisms, especially cultured seafood.

Recently, with the accumulation of evidence that microplastic can be ingested by a variety of marine organisms, microplastic sorption behaviors towards organic contaminants (OCs) have become the subject of more studies due to the concerns about the contaminant vector effect. In this study, the priority microplastics identified in a mariculture farm in Xiangshan Bay, China, including polyethylene (PE) and nylon fibers (i.e., derived from new fishing ropes and nets), were examined for their sorption behaviors. The results indicate that both plastic fibers show linear isotherms towards phenanthrene, a common target hydrophobic organic contaminant (HOC), revealing the characteristics of a partitioning mechanism. The sorption capacity of PE fiber was found to be 1-2 orders of magnitude higher (evaluated by Freundlich parameter log K-F) than that of nylon fiber, suggesting the importance of plastic surface functional groups (i.e., with or without hydrophilic groups). By comparing carbon normalized log K-F with literature data, the organic affinity of PE fiber was found to be 1-2 orders of magnitude lower than that of vectors, such as carbonaceous geosorbents (CG), but was 1-2 orders of magnitude higher than that of marine sediments. Small size and rough surface tended to enhance the sorption of plastic fibers of phenanthrene. In addition, phenol (log K-ow:1.46), a low-hydrophobicity compound, showed approximately 3 orders of magnitude lower sorption amounts onto both fibers compared to phenanthrene (log K-ow:4.46), indicating the selectivity of hydrophobicity. The results of this study demonstrate that the high abundance of plastic fibers distributed in mariculture farms could lead to a higher contaminant transfer effect than marine sediments, and their effects on cultured seafood (e.g., crab and fish) need further investigation. (C) 2018 Elsevier B.V. All rights reserved.

miR-212 as a tumor suppressor has been reported to be downregulated in multiple cancer cells lines and tumor tissues. However, its role in thyroid cancer has nor been investigated. Therefore, the present study aimed to investigate the role of miR-212 in human thyroid cancer and the underlying mechanisms. In the present study, we demonstrated that miR-212 expression was significantly decreased in thyroid cancer specimens and cell lines compared with adjacent normal tissues and normal thyroid cell lines. In addition, we demonstrated that miR-212 downrwegulation in thyroid cancer tissues was negatively associated with lymph node metastasis and advanced clinical stage. Functionally, ectopic expression of miR-212 by transfection with miR-212 mimic significantly inhibited proliferation, colony formation, migration and invasion in TPC-1 cells. In addition, Sirtuin 1 (SIRT1) was identified as a direct target of miR-212 and its expression was inversely correlated with miR-212 expression in thyroid cancer tissues. Overexpression of SIRT1 could effectively rescue miR-212 mimic-induced suppression of cell proliferation, migration and invasion in TPC-1 cells. In vivo, miR-212 overexpression significantly inhibited tumor growth in a nude mice model. In light of these findings, miR-212 may function as a tumor suppressor in thyroid cancer by targeting SIRT1.

Chemotherapy is a powerful cancer treatment but suffers from poor biocompatibility and a lack of tumor targeting. Here, we developed a CD44-targeted polymeric nanocomplex by encapsulating 10-hydroxycamptothecin (HCPT) into hyaluronic acid nanoparticles (HANP) for targeted cancer therapy. In vitro, the HANP/HCPT showed improved cytotoxicity to five cancer cell lines including HT29, A549, MDA-MB-231, HepG2, and MDA-MB-435 versus free HCPT. After systemic administration into MDA-MB-231 breast cancer xenograft, tumor growth was significantly inhibited 5.25 ± 0.21 times in the HANP/HCPT treated group relative to the nontreated group. In addition, the treatment response was also accessed and confirmed by 18F-fluoro-2-deoxy-D-glucose ([18F] FDG) positron emission tomography (PET). The MDA-MB-231 tumors responded to HANP/HCPT 7 days after the first treatment, which benefits treatment strategy adjustment and personalization. No apparent systemic toxic effects were seen in mice treated with HANP/HCPT. In summary, the HANPs have great promise as a targeted drug carrier for cancer chemotherapy. Our HANP platform can also deliver other hydrophobic chemotherapy agents.